Cagrilintide Peptide: Dosage, Reconstitution, CagriSema Results & Protocol (2026)

Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk. As a standalone peptide, it produces 10–12% body weight loss. Combined with semaglutide (CagriSema), 60% of participants in the REDEFINE Phase 3 trial lost more than 20% of their body weight — and 23% lost over 30%. That's the number that changed how people think about amylin-based therapy.

What Is Cagrilintide?

Cagrilintide (AM833) is a synthetic long-acting analogue of amylin, a peptide hormone naturally co-secreted with insulin by pancreatic beta cells after meals. Amylin plays a central role in appetite regulation, gastric emptying, and postprandial glucose control. In people with obesity and type 2 diabetes, amylin function is often impaired — which is part of why appetite regulation breaks down.

Natural amylin has a half-life of just a few minutes, making it impractical as a therapeutic. Cagrilintide was engineered to work once-weekly while producing stronger, more sustained amylin receptor activation than any previous compound. It's currently in Phase 3 trials under the REDEFINE program — both as a monotherapy for obesity and combined with semaglutide as CagriSema.

The key difference from GLP-1 drugs like semaglutide and tirzepatide: cagrilintide works on amylin receptors (AMYR1, AMYR2, AMYR3) rather than GLP-1 receptors. This entirely different pathway is why combining the two produces additive effects — they're hitting separate circuits simultaneously.

How Cagrilintide Works: The Amylin Mechanism

Five distinct mechanisms explain cagrilintide's weight loss effects:

1. Dramatic Gastric Emptying Delay

This is amylin's most powerful effect and the main differentiator from GLP-1 drugs. Cagrilintide slows gastric emptying to a much greater degree than semaglutide — food stays in the stomach 2–3x longer. The result is extended mechanical fullness: people naturally eat smaller portions because their stomach simply hasn't emptied from the last meal. This effect is dose-dependent and continues throughout the dosing week.

2. Central Appetite Suppression

Cagrilintide crosses the blood-brain barrier and activates the area postrema in the brainstem — a region involved in satiety signaling that sits outside the blood-brain barrier. It also acts on the nucleus accumbens, affecting the reward circuitry that drives hedonic eating ("eating when not hungry"). These are different brain regions than those activated by GLP-1 drugs, which is precisely why combining them produces stronger effects than either alone.

3. Glucagon Suppression

Amylin inhibits glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production after meals. This improves glycemic control and contributes indirectly to weight loss by reducing the metabolic swings that drive hunger.

4. Reduced Meal Frequency

The combination of prolonged gastric fullness and central appetite suppression leads people to spontaneously skip snacks and eat less frequently — not through willpower but because the biological drive to eat is simply reduced throughout the week.

5. Preserved Lean Mass

Emerging data from the REDEFINE trials suggests cagrilintide, like other amylin analogues, may help preserve lean muscle mass during weight loss better than GLP-1 monotherapy. The mechanism isn't fully established, but metabolic rate preservation appears better than with GLP-1s alone.

Clinical Trial Results

Monotherapy: Phase 2 Data

The Phase 2 CALM trial (The Lancet, 2021) tested cagrilintide monotherapy in 706 adults with obesity (BMI ≥30) over 26 weeks. Results by dose:

The 2.4mg dose became the standard for Phase 3 development — it hit most of the ceiling effect without meaningfully more side effects than lower doses. Extending treatment beyond 26 weeks continues to produce weight loss, suggesting results at 52+ weeks would be higher.

CagriSema Combination: REDEFINE Phase 3

This is where cagrilintide's full potential shows. REDEFINE-1 combined cagrilintide 2.4mg with semaglutide 2.4mg weekly (CagriSema). Results at 68 weeks:

The additive effect is clear. GLP-1 + amylin works via complementary circuits — appetite suppression is hitting two separate pathways simultaneously. 60% losing more than 20% of body weight is a level of response that's pushing closer to bariatric surgery outcomes in some patients.

Cagrilintide vs Pramlintide

Pramlintide (Symlin) is the only FDA-approved amylin analogue, used for diabetes management. The comparison shows why cagrilintide is the more practical option:

Cagrilintide Dosage Protocol

Cagrilintide requires slow, careful titration. The gastric emptying effect is dose-dependent and rushing causes nausea and vomiting that leads most people to discontinue. The Phase 3 titration schedule:

Some practitioners use an even slower schedule — staying at each dose for 6–8 weeks — particularly for people who are sensitive to GI effects. The 16-week timeline to full dose is notably slower than GLP-1 titration (which typically takes 4–8 weeks) because the gastric emptying effect is more pronounced.

Combining Cagrilintide with Other Peptides

Top Pick Semaglutide S-5 (5mg) Research-grade semaglutide — the GLP-1 component of CagriSema. Combine with cagrilintide for the REDEFINE protocol. Exclusive 50% off — use code PEPTIDEDECK

Buy S-5 (5mg)

CagriSema (Cagrilintide + Semaglutide)

This is the most studied combination and the one Novo Nordisk is developing as a fixed-dose product. The rationale is mechanistic: GLP-1 receptor agonism and amylin receptor agonism hit separate appetite circuits. As REDEFINE-1 showed, the combination produces 22.7% average weight loss vs 15.7% with semaglutide alone — a 7% absolute increase.

Cagrilintide + Retatrutide

No formal clinical data yet, but the mechanistic rationale is strong. Retatrutide targets GLP-1, GIP, and glucagon receptors. Adding amylin receptor agonism would create a four-receptor approach hitting appetite through even more independent pathways. Early community reports suggest the combination is well-tolerated, though the titration complexity increases significantly. See the retatrutide dosing schedule if considering stacking.

Side Effects and Safety

Discontinuation due to side effects in Phase 2 was ~12% at 2.4mg — higher than GLP-1 drugs, primarily because of the intensity of the gastric emptying effect during titration. At steady-state maintenance dose, most GI effects diminish significantly. The key is never rushing titration.

Who Is a Good Candidate?

Cagrilintide makes the most sense for:

• People who've plateaued on GLP-1 monotherapy — adding amylin receptor activation through a completely different mechanism often unlocks further progress
• People pursuing maximum weight loss outcomes — the CagriSema combo is targeting bariatric-level results in the REDEFINE data
• People with type 2 diabetes — amylin analogues address a specific deficiency that's almost universal in T2DM
• People with strong hedonic eating patterns — amylin's action on the nucleus accumbens may help specifically with reward-driven eating that GLP-1s don't fully address

It's less suitable for people who can't commit to the slow titration or who have conditions that make delayed gastric emptying dangerous (severe gastroparesis, certain GI conditions).

Frequently Asked Questions

Reconstituting Cagrilintide: Step-by-Step

Most practical guides skip this entirely. Getting reconstitution right is the difference between an accurate protocol and wasted peptide. The 5mg vial is the standard research format — here's exactly how to handle it.

What You Need

• Cagrilintide lyophilized vial (5mg most common)
• Bacteriostatic water — not sterile water, not saline. Bac water contains 0.9% benzyl alcohol which prevents bacterial growth over the 3–4 weeks you'll draw from the vial.
• Alcohol swabs
• 1mL or 3mL mixing syringe
• U-100 insulin syringes (29–31 gauge) for dosing

Reconstitution Steps

1. Wipe both vial tops with alcohol swabs. Let dry 10 seconds.
2. Draw 2.0 mL of bacteriostatic water into your mixing syringe. This is the optimal volume for a 5mg vial — it gives you 2.5 mg/mL concentration, which keeps all doses within a standard 100-unit insulin syringe range.
3. Insert the needle at an angle so water runs down the inside wall of the glass — not directly onto the lyophilized powder. Add the water slowly.
4. Gently swirl for 30–60 seconds. Never shake — shaking can denature the peptide. The solution should be completely clear. If cloudy or particulate after 2 minutes, discard.
5. Label the vial with the reconstitution date and concentration (2.5 mg/mL). You'll thank yourself in week 3.

Concentration & Syringe Units Reference

This table shows exactly how many insulin syringe units to draw at each dose, depending on how much water you added:

2.0 mL is the recommended volume because it keeps all doses from 0.25mg through 2.4mg within a standard 100-unit syringe. At 3.0 mL, the maintenance dose exceeds syringe capacity — you'd need to split into two injections. At 2.5 mg/mL, the math stays clean: 1mg = 40 units, 2.4mg = 96 units.

How Long Does One Vial Last?

Storage

• Unreconstituted powder: Refrigerate (2–8°C). Protect from light. Do not freeze.
• Reconstituted solution: Refrigerate. Use within 28 days. Do not freeze. Discard if cloudy or discolored.

The Full Titration Protocol with Syringe Units

The titration schedule used in Phase 2 and 3 trials — with exact syringe units at 2.5 mg/mL (recommended concentration):

How to Inject Cagrilintide

Cagrilintide is injected subcutaneously (under the skin) — same as GLP-1 medications. Standard sites:

• Abdomen: 2 inches away from the navel, rotate left/right sides week to week
• Upper thigh: Outer portion, not inner thigh
• Upper arm: Back of the arm (may be harder to self-inject)

Inject once weekly on the same day each week. Consistency matters more for amylin kinetics than it does for GLP-1s — cagrilintide's 7-day half-life means late or missed doses create more pronounced concentration dips. Use the reconstitution calculator to double-check your volumes before injecting.